D2R News
Stay informed about D2R updates by subscribing to our mailing list!
Â鶹AV
On this page, you will find press releases, media coverage, newsletters, and annual reports, among others, allowing you to follow D2R’s latest news. For all interview or information requests from media representatives, please contact D2R.comms [at] mcgill.ca .Ìý
Press Releases
-
D2R announces new round of funding, investing $1.5 million to advance research in RNA therapeutics and to support Â鶹AV Centres and Institutes (December 2024)
-
CQDM partners with D2R to enhance collaborations among researchers and industry in RNA researchÌý(November 2024)
-
Philippe Gros appointed Chief Scientific Officer of D2RÌý(October 2024)
-
D2R welcomes RNA and genomic researchers to Université de Sherbrooke (October 2024)
-
Génome Québec invests up to $500,000 to boost RNA therapeutics innovation in Quebec (October 2024)
-
D2R awards $7.3 million to Advance Research in Genomic-Based RNA Therapeutics (September 2024)
-
$165-million for Â鶹AV’s world-leading inclusive genomics and RNA research program (´¡±è°ù¾±±ôÌý2023)
Media coverage
- (LeDevoir, March 2024)
- (Innovation News Network, February 2024)
- (Maclean's, December 2023)
- (University World News, May 2023)
- (CTV News, April 2023)
- Ìý(Government of Canada, April 2023)
D2R Newsletters
Ìý
Reports & Factsheets
- Â鶹AV's 2023 Annual Report on Research and Innovation. D2R is mentioned on pages 10-12.
- D2R Factsheet
- D2R Booklet
Ìý
